Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
FATE Fate Therapeutics	$1.19 -1.7%	$1.22	$0.66 ▼ $5.92	$136.38M	2.23	2.21 million shs	2.00 million shs
HUMA Humacyte	$2.31 -2.1%	$2.00	$1.15 ▼ $9.79	$358.32M	2	3.83 million shs	2.64 million shs
TSHA Taysha Gene Therapies	$2.46 -4.3%	$2.32	$1.05 ▼ $3.31	$528.07M	1.04	3.06 million shs	9.48 million shs
VIGL Vigil Neuroscience	$7.92	$4.67	$1.31 ▼ $7.95	$369.64M	3.43	744,071 shs	795,906 shs

5G Stocks: The Path Forward is Profitable

Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
FATE Fate Therapeutics	-1.65%	-6.67%	+1.71%	+30.21%	-65.10%
HUMA Humacyte	-2.12%	-2.53%	-1.28%	-30.42%	-61.08%
TSHA Taysha Gene Therapies	-4.28%	-3.15%	-14.88%	+50.00%	-17.17%
VIGL Vigil Neuroscience	0.00%	+0.76%	+242.86%	+319.05%	+104.65%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
FATE Fate Therapeutics	3.9453 of 5 stars	3.1	3.0	4.7	1.8	1.7	0.6
HUMA Humacyte	2.1316 of 5 stars	3.5	1.0	0.0	1.7	2.5	0.6
TSHA Taysha Gene Therapies	3.1673 of 5 stars	4.5	1.0	0.0	2.9	3.3	0.0
VIGL Vigil Neuroscience	3.7515 of 5 stars	4.0	5.0	0.0	2.5	2.5	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
FATE Fate Therapeutics	2.13	Hold	$3.83	222.13% Upside
HUMA Humacyte	3.00	Buy	$11.71	407.11% Upside
TSHA Taysha Gene Therapies	3.00	Buy	$7.57	207.78% Upside
VIGL Vigil Neuroscience	2.00	Hold	$10.80	36.36% Upside

Current Analyst Ratings Breakdown

Latest VIGL, HUMA, TSHA, and FATE Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/12/2025	FATE Fate Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Hold ➝ Hold
6/10/2025	TSHA Taysha Gene Therapies	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$8.00
6/9/2025	HUMA Humacyte	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$25.00
6/3/2025	TSHA Taysha Gene Therapies	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$9.00 ➝ $11.00
6/2/2025	TSHA Taysha Gene Therapies	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$6.00 ➝ $8.00
5/29/2025	TSHA Taysha Gene Therapies	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform
5/29/2025	TSHA Taysha Gene Therapies	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Market Outperform ➝ Market Outperform	$5.00 ➝ $6.00
5/29/2025	TSHA Taysha Gene Therapies	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$7.00 ➝ $9.00
5/28/2025	VIGL Vigil Neuroscience	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Hold	$11.00 ➝ $8.00
5/27/2025	VIGL Vigil Neuroscience	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Neutral	$14.00 ➝ $8.00
5/23/2025	VIGL Vigil Neuroscience	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold

(Data available from 6/21/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
FATE Fate Therapeutics	$13.63M	10.01	N/A	N/A	$2.80 per share	0.43
HUMA Humacyte	$1.57M	228.23	N/A	N/A	($0.41) per share	-5.63
TSHA Taysha Gene Therapies	$8.33M	63.39	N/A	N/A	$0.35 per share	7.03
VIGL Vigil Neuroscience	N/A	N/A	N/A	N/A	$1.75 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
FATE Fate Therapeutics	-$186.26M	-$1.49	N/A	N/A	N/A	-1,318.93%	-47.17%	-34.60%	8/12/2025 (Estimated)
HUMA Humacyte	-$148.70M	-$0.69	N/A	N/A	N/A	N/A	N/A	-73.59%	8/12/2025 (Estimated)
TSHA Taysha Gene Therapies	-$89.30M	-$0.34	N/A	N/A	N/A	-1,201.08%	-104.93%	-50.09%	8/11/2025 (Estimated)
VIGL Vigil Neuroscience	-$84.26M	-$2.05	N/A	N/A	N/A	N/A	-111.70%	-74.67%	8/12/2025 (Estimated)

Latest VIGL, HUMA, TSHA, and FATE Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/15/2025	Q1 2025	TSHA Taysha Gene Therapies	-$0.08	-$0.08	N/A	-$0.08	$1.48 million	$2.30 million
5/13/2025	Q1 2025	FATE Fate Therapeutics	-$0.39	-$0.32	+$0.07	-$0.32	$1.18 million	$1.63 million
5/13/2025	Q1 2025	HUMA Humacyte	-$0.19	-$0.10	+$0.09	$0.28	$0.46 million	$0.52 million
5/7/2025	Q1 2025	VIGL Vigil Neuroscience	-$0.53	-$0.49	+$0.04	-$0.49	N/A	N/A
3/28/2025	Q4 2024	HUMA Humacyte	-$0.23	-$0.16	+$0.07	-$0.16	$0.64 million	$7.23 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
FATE Fate Therapeutics	N/A	N/A	N/A	N/A	N/A
HUMA Humacyte	N/A	N/A	N/A	N/A	N/A
TSHA Taysha Gene Therapies	N/A	N/A	N/A	N/A	N/A
VIGL Vigil Neuroscience	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
FATE Fate Therapeutics	N/A	8.81	8.81
HUMA Humacyte	0.36	3.68	3.28
TSHA Taysha Gene Therapies	0.77	5.35	5.35
VIGL Vigil Neuroscience	N/A	2.97	2.97

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
FATE Fate Therapeutics	97.54%
HUMA Humacyte	44.71%
TSHA Taysha Gene Therapies	77.70%
VIGL Vigil Neuroscience	83.64%

Insider Ownership

Company	Insider Ownership
FATE Fate Therapeutics	5.51%
HUMA Humacyte	5.10%
TSHA Taysha Gene Therapies	3.78%
VIGL Vigil Neuroscience	18.01%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
FATE Fate Therapeutics	550	114.60 million	108.29 million	Optionable
HUMA Humacyte	150	155.12 million	147.21 million	Optionable
TSHA Taysha Gene Therapies	180	214.66 million	206.55 million	Optionable
VIGL Vigil Neuroscience	40	46.67 million	38.27 million	Not Optionable

VIGL, HUMA, TSHA, and FATE Headlines

Recent News About These Companies

Vigil Neuroscience, Inc. (NASDAQ:VIGL) Receives $10.80 Consensus Price Target from Analysts

June 20 at 1:20 AM | americanbankingnews.com

Vigil Neuroscience, Inc. (NASDAQ:VIGL) Receives Consensus Rating of "Hold" from Analysts

June 17, 2025 | marketbeat.com

Two Sigma Investments LP Acquires 41,836 Shares of Vigil Neuroscience, Inc. (NASDAQ:VIGL)

June 12, 2025 | marketbeat.com

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates HURA and VIGL on Behalf of Shareholders

June 9, 2025 | prnewswire.com

Wall Street Analysts Think Vigil Neuroscience (VIGL) Could Surge 26.9%: Read This Before Placing a Bet

June 9, 2025 | zacks.com

Squarepoint Ops LLC Acquires New Shares in Vigil Neuroscience, Inc. (NASDAQ:VIGL)

June 9, 2025 | marketbeat.com

Millennium Management LLC Boosts Holdings in Vigil Neuroscience, Inc. (NASDAQ:VIGL)

June 9, 2025 | marketbeat.com

Jane Street Group LLC Invests $83,000 in Vigil Neuroscience, Inc. (NASDAQ:VIGL)

June 9, 2025 | marketbeat.com

Vigil Neuroscience, Inc. (NASDAQ:VIGL) Holdings Lifted by Two Sigma Advisers LP

June 8, 2025 | marketbeat.com

Vigil Neuroscience halts Phase 2 trial for ALSP treatment

June 5, 2025 | investing.com

Vigil’s TREM2 Antibody for Rare Brain Disease Flunks Phase II Trial

June 5, 2025 | biospace.com

VIGIL SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation into Fairness of Vigil Neuroscience, Inc. (NASDAQ: VIGL) Proposed Shareholder Buyout and Encourages Investors ...

June 5, 2025 | morningstar.com

Disappointing results see Vigil Neuro drop iluzanebart development

June 4, 2025 | thepharmaletter.com

VIGIL SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation into Fairness of Vigil Neuroscience, Inc. (NASDAQ: VIGL) Proposed Shareholder Buyout and Encourages Investors to Contact the Firm

June 4, 2025 | prnewswire.com

Vigil Neuroscience Provides Update on Iluzanebart Phase 2 IGNITE Trial in ALSP

June 4, 2025 | globenewswire.com

Should You Buy Vigil Neuroscience, Inc. (VIGL) After Golden Cross?

June 2, 2025 | zacks.com

HC Wainwright Has Bearish Forecast for VIGL FY2026 Earnings

May 30, 2025 | marketbeat.com

Stifel cuts Vigil Neuroscience stock rating, lowers target to $8

May 29, 2025 | investing.com

Vigil Neuroscience (NASDAQ:VIGL) Downgraded by Stifel Nicolaus to Hold

May 29, 2025 | marketbeat.com

Stifel Downgrades Vigil Neuroscience (VIGL)

May 29, 2025 | msn.com

HC Wainwright Reiterates "Neutral" Rating for Vigil Neuroscience (NASDAQ:VIGL)

May 28, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

VIGL, HUMA, TSHA, and FATE Company Descriptions

Fate Therapeutics NASDAQ:FATE

$1.19 -0.02 (-1.65%)

Closing price 06/20/2025 04:00 PM Eastern

Extended Trading

$1.20 +0.01 (+0.84%)

As of 06/20/2025 06:36 PM Eastern

Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma, and FT522, to treat lymphoma and autoimmune disorders. Its CAR T-cell programs include FT819 to treat hematologic malignancies and solid tumors, and FT825 to treat solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of cancer. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.

Humacyte NASDAQ:HUMA

$2.31 -0.05 (-2.12%)

Closing price 06/20/2025 04:00 PM Eastern

Extended Trading

$2.32 +0.00 (+0.22%)

As of 06/20/2025 07:33 PM Eastern

Humacyte, Inc. engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection. It is developing a portfolio of HAVs, which would target the vascular repair, reconstruction, and replacement market, including vascular trauma; arteriovenous access for hemodialysis; peripheral arterial disease; pediatric heart surgery; and coronary artery bypass grafting, as well as for the delivery of cellular therapy, including pancreatic islet cell transplantation to treat Type 1 diabetes. The company was founded in 2004 and is headquartered in Durham, North Carolina.

Taysha Gene Therapies NASDAQ:TSHA

$2.46 -0.11 (-4.28%)

Closing price 06/20/2025 04:00 PM Eastern

Extended Trading

$2.48 +0.02 (+0.81%)

As of 06/20/2025 06:09 PM Eastern

Taysha Gene Therapies, Inc., a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis. Taysha Gene Therapies, Inc. has a strategic partnership with The University of Texas Southwestern Medical Center. Taysha Gene Therapies, Inc. was incorporated in 2019 and is headquartered in Dallas, Texas.

Vigil Neuroscience NASDAQ:VIGL

$7.92 0.00 (0.00%)

Closing price 06/20/2025 04:00 PM Eastern

Extended Trading

$7.94 +0.02 (+0.25%)

As of 06/20/2025 06:35 PM Eastern

Vigil Neuroscience, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel immune cells of the brain. Its lead candidate is VGL101(Iluzanebart), a human monoclonal antibody agonist targeting human triggering receptor expressed on myeloid cells 2 and is in a Phase 2 trial in patients with adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP), a rare and fatal neurodegenerative disease. The company is also developing VG-3927, an orally-available small molecule TREM2 agonist to treat common neurodegenerative diseases associated with microglial dysfunction, with an initial focus on Alzheimer's disease in genetically defined subpopulations, which is being evaluated in a Phase 1 clinical trial. It has license agreement with Amgen Inc. to commercially develop, manufacture, use, distribute, and sell therapeutic products containing compounds that bind to TREM2. The company was incorporated in 2020 and is headquartered in Watertown, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time